Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

112.87 -1.99 (-1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher
There are still plenty of growth opportunities left for these businesses. 
Via The Motley Fool
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
These stocks look cheap if you take a long-term view. 
Via The Motley Fool
Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart?
Via Benzinga
Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS 
Via Benzinga
2 Cannabis Stocks to Buy for the Long Haul
Don't give up on this sector too quickly. 
Via The Motley Fool
2 Growth Stocks to Buy Heading Into 2023
These biotechs are far from having achieved their full potential. 
Via The Motley Fool
Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks
Via Benzinga
6 Analysts Have This to Say About Jazz Pharmaceuticals
Via Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Via Benzinga
Is Axsome Therapeutics Stock a Buy Now?
The company seems to be coming into its own. 
Via The Motley Fool
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Better Buy: Moderna vs Axsome
Revenue prospects look promising for both of these biotech companies. 
Via The Motley Fool
Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today
U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation... 
Via Benzinga
After Jumping 100%, Is Axsome a Buy Before 2023?
Axsome's revenue story is just getting started. 
Via The Motley Fool
Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday
Wells Fargo raised Netflix, Inc. (NASDAQ: NFLX) price target from $300 to $400. Wells Fargo also upgraded the stock from Equal Weight to Overweight. Netflix shares rose 0.6% to close at $310.26 on... 
Via Benzinga
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
These biotech players beat the bear market this year. 
Via The Motley Fool
3 Fierce Stocks That Are Screaming Buys in December
Here are three winners in the making. 
Via The Motley Fool
Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) caregiver survey that showed a substantial proportion of caregivers... 
Via Benzinga
Biotech Space Offers Reward In 2023 Despite Economic Risks
Despite the economic headwinds, the mid-to long-term outlook for the biotech space remains strong, and investors who are able to take advantage of undervalued biotech stocks may be well-positioned for... 
Via Talk Markets
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
Q3 Proves To Be Another Tough Quarter For Cannabis
It’s been a tough year for cannabis investors and Q3 offered little relief. 
Via Talk Markets
Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling
The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Want to Double Your Money? Buying These Stocks Could be a Genius Move
These stocks are undervalued considering their long-term growth potential. 
Via The Motley Fool
Prediction: This Growth Stock Could Double in 2023
The next year should be a busy one for this drugmaker. 
Via The Motley Fool
Three CBD Stocks to Dominate a Budding Industry
The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity. 
Via MarketBeat
Topics Cannabis
Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling
Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent. 
Via Benzinga
Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent
Via Benzinga
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
Innovative products and services could keep these companies growing. 
Via The Motley Fool
3 Top Cannabis Stocks to Buy in November
These solid performers are managing to grow revenue in a difficult environment. 
Via The Motley Fool
2 Dirt Cheap Growth Stocks to Buy and Hold for Years
In the long run, these stocks could deliver great returns. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.